The acquisition reflects Johnson & Johnson’s push to strengthen its position in antibody engineering and next-generation oncology modalities
Broadening access for children & patients with inhibitor-complicated hemophilia
We have the chance to build an IP estate that goes hand in hand with our generic pharmaceutical strength and build proprietary biological platforms
This alliance, covering up to 12 antibody drugs, highlights the growing trend of large-scale collaborations between Chinese biotech firms and global pharmaceutical giants
The newly licensed platform enables precise control over both the drug-to-antibody ratio and payload attachment sites in single- and dual-payload ADCs
Madhav Bhutada says overdependence on large CDMOs and delayed engagement can increase development costs by up to 40% and slow clinical progress
SERB has a substantial European commercial presence and a successful track record in critical care and rare disease commercialization
The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon peptide platform
The company intends to file an IND submission by the end of this year and begin clinical studies in 2027
The decision marks a significant expansion for Pfizer’s once-weekly injectable therapy
Subscribe To Our Newsletter & Stay Updated
